Wikidata:WikiProject Chronic Pain/Treatments

Lists edit

Naltrexone (w, wd, src) Naltrexone is also a partial inverse agonist, and this property is exploited in treatment of opioid addiction, as a sustained course of low-dose naltrexone can reverse the altered homeostasis which results from long-term abuse of opioid agonist drugs.
- Low-dose naltrexone (w, wd, src) Low doses of naltrexone block opioid receptors and toll-like receptor 4 on microglia cells. Two clinical trials of 4.5-mg daily doses of naltrexone in women with fibromyalgia show an effect after 2 months. Most patients feel better and their symptoms slowly decline, Younger said. Side effects are few, the most common being vivid dreams. One hypothesis behind low-dose naltrexone's mechanism of action is that inhibiting opioid receptors at low doses might cause the body to increase production of endorphins and upregulate the immune system; it may also antagonize Toll-like receptor 4 that are found on macrophages, including microglia, and any reported anti-inflammatory effects might be due to that. LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors.^[1]
- dextro-naltrexone (w, wd, src) stereoisomer of naltrexone which is active at microglia receptors but has no activity on opioid receptors ^[2]
curcumin (w, wd, src) ^[2]

Cannabidiol (w, wd, src) CBD is a CR1 and CR2 inverse antagonist. It has no psychotic effect.
Tetrahydrocannabinol (w, wd, src) THC is a CR1 and CR2 partial agonist. It has psychotic effects.

Dextroamphetamine (w, wd, src) Can be used in case of hypofunction of the sympathetic nervous system. ex.
CR4056 (w, wd, src) an analgesic drug candidate with a novel mechanism of action, acting as a ligand for the imidazoline receptor I2. It showed promising results in animal studies against various types of neuropathic pain, and has reached Phase II human clinical trials as a potential treatment for pain associated with osteoarthritis.
chelation therapy (w, wd, src) treatment of heavy metal intoxication